CasNo.82640-04-8,Raloxifene hydrochloride 99%,(82640-04-8) Suppliers

1 Kilogram	FOB Price: USD 1.0000

Min.Order :1 Kilogram
Purity: 98.5-101.5%
Payment Terms : L/C,T/T,

Keywords

Raloxifene hcl Raloxifene HCL Raloxifene HCL Raloxifene HCL Raloxifene HCL Raloxifene HCL Raloxifene HCL Raloxifene HCL

Quick Details

Appearance:yellow
Application:Raloxifene hydrochloride//cas:82640-04-8
PackAge:as your requirement
ProductionCapacity:23|Kilogram|Day
Storage:Avoid light, sealed
Transportation:by air or by sea

Superiority:

Raloxifene HCL Raloxifene HCL Raloxifene HCL

Raloxifene (marketed as Evista by Eli Lilly and Company) is an oralselective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women.

In 2006, the National Cancer Institute announced that raloxifene was as effective as tamoxifen in reducing the incidence of breast cancer in postmenopausal women at increased risk. A major adverse effect of tamoxifen is uterine cancer; raloxifene caused fewer cases of uterine cancer. Tamoxifen increased the risk of cataracts, but raloxifene did not. Both groups had more blood clots in veins and the lungs, but that side effect was more common with tamoxifen than raloxifene.^[2]^[3]^[4] On September 14, 2007, the U.S. Food and Drug Administration announced approval of raloxifene for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.^[5]

An editorial in Lancet Oncology criticized the way that information about the drug was released.^[6]

Details:

Raloxifene HCL Raloxifene HCL Raloxifene HCL

Raloxifene



Systematic (IUPAC) name
[6-hydroxy-2-(4-hydroxyphenyl)- benzothiophen-3-yl]- [4-[2-(1-piperidyl)ethoxy]phenyl] -methanone
Clinical data
Trade names	Evista
AHFS/Drugs.com	monograph
MedlinePlus	a698007
Licence data	EMA:Link, US FDA:link
Pregnancy cat.	X (AU) X (US)
Legal status	Prescription only
Routes	Oral
Pharmacokinetic data
Bioavailability	2%
Protein binding	95%
Metabolism	Gut glucuronidation^[1] CYP system not involved
Half-life	27.7 hours
Excretion	Fecal
Identifiers
CAS number	84449-90-1
ATC code	G03XC01
PubChem	CID 5035
IUPHAR ligand	2820
DrugBank	DB00481
ChemSpider	4859
UNII	YX9162EO3I
ChEBI	CHEBI:8772
ChEMBL	CHEMBL81
Chemical data
Formula	C₂₈H₂₇N O₄S
Mol. mass	473.584 g/mol